Lifeward (LFWD) Company Report

Lifeward Ltd. entered into a Securities Purchase Agreement with Oramed and other investors to issue up to $20,000,000.00 in senior secured convertible notes and accompanying warrants.
The notes will accrue interest at 8.0% per annum, increasing to 15.0% upon an event of default, and are convertible into Ordinary Shares at an initial price of $0.45 per share. Interest payments are semi-annual, commencing December 31, 2026.
The funding of the second $10,000,000.00 tranche of notes is contingent on shareholder approval and either a 150% increase in ReWalk Unit Sales or the company's Ordinary Shares closing at or above $1.15 per share for ten consecutive trading days.

Jan 13, 2026, 1:15 PM

Lifeward expands international distribution of ReWalk Exoskeleton

LFWD

New Projects/Investments

Product Launch

Lifeward Ltd. has expanded patient access to its ReWalk Personal Exoskeleton through a new international distribution agreement with Singapore-based Verita Neuro.
Verita Neuro will be the exclusive distributor of ReWalk initially in Mexico, Thailand, and the United Arab Emirates.
This collaboration supports Lifeward’s long-term growth strategy by extending its commercial footprint into new international markets through a partner-led, capital-efficient model, integrating in-patient training and rehabilitation.
Lifeward estimates that over 7 million global spinal cord injury survivors could potentially benefit from ReWalk, representing an estimated $1.75 billion total addressable market.

Dec 17, 2025, 1:00 PM

Lifeward Reports Q3 2025 Financial Results and Reaffirms Full-Year Guidance

LFWD

Earnings

Guidance Update

Revenue Acceleration/Inflection

Lifeward reported Q3 2025 revenue of $6.2 million, an increase of 1.1% year-over-year from $6.1 million in Q3 2024 and an 8% increase quarter-over-quarter from $5.7 million in Q2 2025.
The company achieved a non-GAAP operating loss of $3 million in Q3 2025, representing a 27% reduction compared to $4.1 million in the same period last year, driven by operational efficiencies and lower R&D spending.
Lifeward ended Q3 2025 with $2 million in cash and cash equivalents and subsequently secured a $3 million loan with AuraMed, providing sufficient liquidity to fund operations into Q4 2026.
The company reaffirmed its full-year 2025 guidance, projecting revenue in the range of $24-$26 million and a non-GAAP net loss between $12-$14 million.
Operational improvements include a 16% reduction in quarterly cash burn, record ReWalk placements for Medicare beneficiaries, and expanded access to the European market following CE mark approval.

Nov 14, 2025, 1:30 PM

Lifeward Ltd. Reports Q3 2025 Financial Results and Secures New Loan

LFWD

Earnings

Guidance Update

Debt Issuance

Lifeward Ltd. reported Q3 2025 revenue of $6.2 million, a 1% increase from Q3 2024, and a non-GAAP net loss of $3.0 million, or $0.19 per share.
The company achieved a record quarter for ReWalk systems placed for Medicare beneficiaries and saw a 16% year-over-year decrease in quarterly cash burn to $3.8 million.
Lifeward Ltd. secured a $3.0 million loan agreement with Oramed Ltd. on November 14, 2025, to support ongoing operations.
The company reaffirmed its full-year 2025 guidance, expecting revenue between $24 million and $26 million and a non-GAAP net loss between $12 million and $14 million.